Understanding Menopause and HRT Amid FDA's Recent Veozah Labeling Update
The FDA's Update on Veozah and Its Implications for Menopause and HRT
The FDA has recently updated the labeling for Veozah due to reports of acute mixed hepatocellular cholestatic drug-induced liver injury. For patients undergoing menopause and considering HRT, this raises significant questions about the safety and efficacy of current treatment options.
Key Points from the FDA Report
- Increased Awareness: The report indicates the necessity for healthcare providers to monitor liver function in patients prescribed Veozah.
- Potential Risks: Patients should be informed about the possibility of liver injury associated with this medication.
- Consultation Recommended: Discuss alternative HRT options with healthcare professionals before making treatment decisions.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.